

# Sam S Yoon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4805385/publications.pdf>

Version: 2024-02-01

87  
papers

4,408  
citations

117571

34  
h-index

106281

65  
g-index

88  
all docs

88  
docs citations

88  
times ranked

7080  
citing authors

#	ARTICLE	IF	CITATIONS
1	Extent of gastrectomy and lymphadenectomy for gastric adenocarcinoma. <i>Surgical Oncology</i> , 2022, 40, 101689.	0.8	3
2	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	0.8	13
3	Open and minimally invasive gastrectomy in Eastern and Western patient populations: A review of the literature and reasons for differences in outcomes. <i>Journal of Surgical Oncology</i> , 2022, 126, 279-291.	0.8	3
4	Treatment for local control of retroperitoneal and pelvis sarcomas: A review of the literature. <i>Surgical Oncology</i> , 2022, 43, 101814.	0.8	5
5	Increased CD44 Expression and MEK Activity Predict Worse Prognosis in Gastric Adenocarcinoma Patients Undergoing Gastrectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1147-1155.	0.9	6
6	Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling. <i>Oncogene</i> , 2021, 40, 922-936.	2.6	20
7	Surveillance Endoscopy in the Management of Hereditary Diffuse Gastric Cancer Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 189-191.	2.4	15
8	Histologic Subtype Defines the Risk and Kinetics of Recurrence and Death for Primary Extremity/Truncal Liposarcoma. <i>Annals of Surgery</i> , 2021, 273, 1189-1196.	2.1	11
9	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. <i>Annals of Surgery</i> , 2021, 273, 128-138.	2.1	62
10	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. <i>Annals of Surgical Oncology</i> , 2021, 28, 4829-4838.	0.7	14
11	ASO Visual Abstract: Association of Obesity with Worse Operative and Oncologic Outcomes Among Patients Undergoing Gastric Cancer Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 410-411.	0.7	1
12	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 7040-7050.	0.7	0
13	PIK3R3, part of the regulatory domain of PI3K, is upregulated in sarcoma stem-like cells and promotes invasion, migration, and chemotherapy resistance. <i>Cell Death and Disease</i> , 2021, 12, 749.	2.7	16
14	FOXC1 modulates stem-like cell properties and chemoresistance through Hedgehog and EMT signaling in gastric adenocarcinoma. <i>Molecular Therapy</i> , 2021, , .	3.7	4
15	PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas. <i>Oncogenesis</i> , 2021, 10, 12.	2.1	38
16	Radiation Therapy in Primary Soft Tissue Sarcoma of the Superficial Trunk. <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	0
17	Long-Term Survival after Minimally Invasive Versus Open Gastrectomy for Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of Patients in the United States and China. <i>Annals of Surgical Oncology</i> , 2020, 27, 802-811.	0.7	10
18	Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis. <i>Cell Metabolism</i> , 2020, 31, 174-188.e7.	7.2	51

#	ARTICLE	IF	CITATIONS
19	Performance of the American College of Surgeons NSQIP Surgical Risk Calculator for Total Gastrectomy. <i>Journal of the American College of Surgeons</i> , 2020, 231, 650-656.	0.2	7
20	ASO Author Reflections: Minimally Invasive Surgery for Gastric Cancer—Has the Future Arrived?. <i>Annals of Surgical Oncology</i> , 2020, 27, 744-745.	0.7	0
21	CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer. <i>British Journal of Cancer</i> , 2020, 123, 1131-1144.	2.9	10
22	Indications for Total Gastrectomy in <i>CDH1</i> Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. <i>JAMA Surgery</i> , 2020, 155, 1050.	2.2	34
23	CDX1 Expression Induced by CagA-Expressing <i>Helicobacter pylori</i> Promotes Gastric Tumorigenesis. <i>Molecular Cancer Research</i> , 2019, 17, 2169-2183.	1.5	25
24	KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis. <i>Molecular Cancer Research</i> , 2019, 17, 1945-1957.	1.5	31
25	Abstract 4680: KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis. , 2019, , .		1
26	Abstract 4680: KRAS activation in gastric adenocarcinoma stimulates epithelial-to-mesenchymal transition to cancer stem-like cells and promotes metastasis. , 2019, , .		1
27	The New American Joint Commission on Cancer Staging System for Soft Tissue Sarcomas: Splitting versus Lumping. <i>Annals of Surgical Oncology</i> , 2018, 25, 1101-1102.	0.7	14
28	Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. <i>Annals of Surgery</i> , 2018, 267, 105-113.	2.1	103
29	Comparison of Outcomes for Elderly Gastric Cancer Patients at Least 80 Years of Age Following Gastrectomy in the United States and China. <i>Annals of Surgical Oncology</i> , 2018, 25, 3629-3638.	0.7	6
30	<i>KMT2C</i> Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2018, 24, 6556-6569.	3.2	70
31	Platelet-derived growth factor receptor- $\alpha$ and - $\beta$ promote cancer stem cell phenotypes in sarcomas. <i>Oncogenesis</i> , 2018, 7, 47.	2.1	28
32	Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. <i>Advances in Radiation Oncology</i> , 2017, 2, 85-93.	0.6	57
33	Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. <i>Molecular Cancer Research</i> , 2017, 15, 1106-1116.	1.5	74
34	Linear-Stapled Side-to-Side Esophagojejunostomy with Hand-Sewn Closure of the Common Enterotomy After Prophylactic and Therapeutic Total Gastrectomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 712-722.	0.9	8
35	Comparison of Young Patients with Gastric Cancer in the United States and China. <i>Annals of Surgical Oncology</i> , 2017, 24, 3964-3971.	0.7	25
36	Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression. <i>Cancer Research</i> , 2017, 77, 5349-5359.	0.4	56

#	ARTICLE	IF	CITATIONS
37	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	0.8	3
38	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 828-837.	0.6	6
39	Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 4238-4246.	0.7	6
40	Decreased length of stay and earlier oral feeding associated with standardized postoperative clinical care for total gastrectomies at a cancer center. Surgery, 2016, 160, 607-612.	1.0	10
41	Laparoscopic Versus Open Surgery for Gastric Adenocarcinoma. Annals of Surgery, 2016, 264, 223-225.	2.1	7
42	Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield. Journal of Gastrointestinal Surgery, 2016, 20, 165-171.	0.9	22
43	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Journal of Clinical Oncology, 2016, 34, 460-468.	0.8	363
44	Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. Clinical Cancer Research, 2016, 22, 971-983.	3.2	89
45	Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1 $\alpha$ inhibition, and hypoxia-activated chemotherapy. Oncotarget, 2016, 7, 42844-42858.	0.8	18
46	Surgical management of retroperitoneal and pelvic sarcomas. Journal of Surgical Oncology, 2015, 111, 553-561.	0.8	13
47	Vascular Endothelial Growth Factor A Inhibition in Gastric Cancer. Gastric Cancer, 2015, 18, 33-42.	2.7	55
48	Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E3402-11.	3.3	90
49	Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1508-1515.	0.7	26
50	CD44 Expression Denotes a Subpopulation of Gastric Cancer Cells in Which Hedgehog Signaling Promotes Chemotherapy Resistance. Clinical Cancer Research, 2014, 20, 3974-3988.	3.2	159
51	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. Annals of Surgical Oncology, 2014, 21, 1130-1137.	0.7	29
52	MDCT imaging of Alloderm biologic mesh spacers in the abdomen and pelvis " preliminary experience. Clinical Imaging, 2014, 38, 279-282.	0.8	5
53	Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. Practical Radiation Oncology, 2014, 4, 167-173.	1.1	22
54	An Active Learning Approach for Rapid Characterization of Endothelial Cells in Human Tumors. PLoS ONE, 2014, 9, e90495.	1.1	24

#	ARTICLE	IF	CITATIONS
55	Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1. International Journal of Cancer, 2013, 132, 29-41.	2.3	35
56	Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer. Practical Radiation Oncology, 2013, 3, e11-e19.	1.1	23
57	Extended Lymphadenectomy in Gastric Cancer Is Debatable. World Journal of Surgery, 2013, 37, 1773-1777.	0.8	30
58	D2 Lymphadenectomy with Surgical Ex Vivo Dissection into Node Stations for Gastric Adenocarcinoma Can Be Performed Safely in Western Patients and Ensures Optimal Staging. Annals of Surgical Oncology, 2013, 20, 2991-2999.	0.7	25
59	Noncurative Gastrectomy for Gastric Adenocarcinoma Should only be Performed in Highly Selected Patients. Annals of Surgical Oncology, 2013, 20, 3512-3518.	0.7	28
60	Prognostic Factors and Outcomes of Patients with Myxofibrosarcoma. Annals of Surgical Oncology, 2013, 20, 80-86.	0.7	105
61	Surgical placement of biologic mesh spacers prior to external beam radiation for retroperitoneal and pelvic tumors. Practical Radiation Oncology, 2013, 3, 199-208.	1.1	15
62	Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage. Molecular Cancer Therapeutics, 2013, 12, 2591-2600.	1.9	71
63	Association of perioperative radiation therapy with outcome in 204 patients with primary retroperitoneal sarcoma: A two-institution study.. Journal of Clinical Oncology, 2013, 31, 10520-10520.	0.8	0
64	Comparison of a Lymph Node Ratio-Based Staging System With the 7th AJCC System for Gastric Cancer. Annals of Surgery, 2012, 255, 478-485.	2.1	175
65	Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials. Current Angiogenesis, 2012, 1, 169-179.	0.1	19
66	Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: A 10-year follow-up study.. Journal of Clinical Oncology, 2012, 30, 10058-10058.	0.8	0
67	Varying Lymphadenectomies for Gastric Adenocarcinoma in the East Compared with the West: Effect on Outcomes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 250-255.	1.8	2
68	Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1081-1090.	0.4	77
69	Prophylactic total gastrectomy for individuals with germline CDH1 mutation. Surgery, 2011, 149, 347-355.	1.0	64
70	Proton-Beam, Intensity-Modulated, and/or Intraoperative Electron Radiation Therapy Combined with Aggressive Anterior Surgical Resection for Retroperitoneal Sarcomas. Annals of Surgical Oncology, 2010, 17, 1515-1529.	0.7	97
71	Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East?. Oncologist, 2009, 14, 871-882.	1.9	51
72	Efficacy of Sunitinib and Radiotherapy in Genetically Engineered Mouse Model of Soft-Tissue Sarcoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1207-1216.	0.4	40

#	ARTICLE	IF	CITATIONS
73	Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. PLoS ONE, 2009, 4, e8075.	1.1	71
74	Targeted Deletion of the Calcineurin Inhibitor DSCR1 Suppresses Tumor Growth. Cancer Cell, 2008, 13, 420-431.	7.7	121
75	Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors. Clinical Cancer Research, 2008, 14, 1529-1539.	3.2	157
76	Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2360.	3.8	394
77	A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine, 2007, 13, 992-997.	15.2	274
78	Angiogenic Profile of Soft Tissue Sarcomas Based on Analysis of Circulating Factors and Microarray Gene Expression. Journal of Surgical Research, 2006, 135, 282-290.	0.8	57
79	Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2006, 13, 353-362.	0.7	59
80	Adult primary retroperitoneal teratoma. Surgery, 2005, 137, 663-664.	1.0	7
81	Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor A. Cancer Research, 2005, 65, 5881-5889.	0.4	134
82	The Diminishing Role of Surgery in the Treatment of Gastric Lymphoma. Annals of Surgery, 2004, 240, 28-37.	2.1	98
83	Diagnosis, Management, and Outcomes of 115 Patients with Hepatic Hemangioma. Journal of the American College of Surgeons, 2003, 197, 392-402.	0.2	195
84	Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecologic Oncology, 2003, 91, 383-388.	0.6	51
85	CD44s expression in human colon carcinomas influences growth of liver metastases. International Journal of Cancer, 2000, 85, 523-526.	2.3	48
86	CD44s expression in human colon carcinomas influences growth of liver metastases. , 2000, 85, 523.		1
87	Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases. Oncologist, 1999, 4, 197-208.	1.9	104